Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380635 · ClinicalTrials.gov registry record · Phase 2
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by Soligenix.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT05380635 is a Phase 2 study that has completed, run by Soligenix. The registered enrollment target is 9 participants.
The verdict
NCT05380635, a Phase 2 study, has completed, sponsored by Soligenix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
Interventions
- DRUG Hypericin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2022-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05380635
The ClinicalTrials.gov registry entry for NCT05380635 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Soligenix, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypericin is the first listed.
NCT05380635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05380635 about?
NCT05380635 is a clinical study titled "PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma". To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
What is the current status of trial NCT05380635?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2022-05-09. Estimated completion is 2022-08-16.
What interventions are being tested in trial NCT05380635?
The interventions under investigation include: Hypericin (DRUG).
Who is sponsoring clinical trial NCT05380635?
This trial is sponsored by Soligenix, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.